Functional Genetics Announces Two Separate Awards from the National Institute of Allergy and Infectious Diseases to Develop Broad Spectrum Antivirals
Functional Genetics, Inc. today announced the awarding of two different Phase II SBIR awards from the National Institute of Allergy and Infectious Diseases (NIAID) to pursue innovative approaches for antibody-based targeting of infectious diseases. Under the terms of the agreement, Functional... - June 29, 2010
Gates Foundation Funds Functional Genetics, Inc. to Study TSG101 Antibody Targeting of HIV-Infected Cells
Functional Genetics, Inc. today announced a grant from the Bill & Melinda Gates Foundation to pursue an innovative approach for antibody-based targeting of HIV/AIDS. Under the terms of the agreement, Functional Genetics will investigate the use of TSG101 antibody targeting of HIV-infected cells... - November 23, 2009
Functional Genetics Announces Discovery of Target That Regulates Alzheimer's Disease
Investigators at Functional Genetics, working with scientists at the Burnham Institute for Medical Research, Stanford University and Rockefeller University, have utilized its proprietary RHGP discovery technology to identify a novel gene (Rps23r1) in mice that reduces the accumulation of two toxic... - November 14, 2009
Functional Genetics Highlights Progress in the Development of Broad-Spectrum Antiviral at the 22nd International Conference on Antiviral Research
Functional Genetics, Inc. today announced that two platform presentations and three poster abstracts on progress being made in its broad-spectrum antiviral programs will be presented during the International Conference on Antiviral Research in Miami, FL from May 4 to 7. “The development of... - May 06, 2009
Functional Genetics, Inc. Announces Agreement with Elanco, a Division of Eli Lilly and Company
Functional Genetics, Inc., a biotechnology research and development company, announced today that it has reached a collaborative research, license and commercialization agreement with Elanco, the animal health division of Eli Lilly and Company. The agreement establishes the framework for... - December 09, 2008
Functional Genetics, Inc. Receives Award to Discover New Opportunities to Combat HIV Infection
Functional Genetics, Inc. Announces a New Award from the National Institute of Allergy and Infectious Diseases to Utilize Its Core Random Homozygous Gene Perturbation and Host-Oriented Therapeutics Technologies to Identify and Validate New Therapeutic Approaches to Combat HIV Infection - June 03, 2007
Functional Genetics, Inc. Announces Two Separate Awards from the United States Defense Threat Reduction Agency (DTRA) to Combat Viral Diseases
Functional Genetics, Inc. announced today that it has received two different awards from the United States Defense Threat Reduction Agency for the discovery and development of therapeutics for Ebola virus and other viral pathogens. "These awards from DTRA will greatly assist our mission of... - December 01, 2006